文献速递临床试验与 GCP医学人工智能与信息学

人工智能指导持续性心房颤动个体化治疗:一项随机对照试验

Artificial intelligence for individualized treatment of persistent atrial fibrillation: a randomized controlled trial.
PubMed 文献 · Nat Med · 2025-02-14

这项多中心、随机、对照、双盲、优效性试验纳入药物难治性持续性心房颤动患者,比较在肺静脉隔离(PVI)基础上由人工智能(AI)算法检测时空离散区域并针对性消融(定制组,n=187)与常规单纯PVI(解剖组,n=183)的疗效。术后12个月,定制组88%患者无房性心律失常复发,解剖组为70%(优效性log-rank P<0.0001),但两组无任何房性心律失常事件无显著差异,安全性终点无差异,定制组手术和消融时间延长一倍。

要点

  • AI指导的时空离散区域消融联合PVI在12个月无房颤复发方面优于单纯PVI(88% vs 70%,P<0.0001)。
  • 两组无任何房性心律失常事件无显著差异。
  • 安全性终点无差异,但定制组手术和消融时间延长一倍。

核心结论

  • AI指导的时空离散区域消融联合PVI在持续性及长程持续性心房颤动患者1年随访中消除房颤方面优于单纯PVI。
  • 为长期维持窦性心律,可能需要消融后续出现的规则性房性心动过速。

研究设计与样本

  • 多中心、随机、对照、双盲、优效性试验,纳入药物难治性持续性心房颤动患者。
  • 患者随机分配至定制组(AI算法检测时空离散区域消融联合PVI,n=187,女性23%)或解剖组(常规单纯PVI,n=183,女性19%)。

主要发现

  • 主要疗效终点为单次消融术后12个月无记录到的房颤(伴或不伴抗心律失常药物),定制组达到88%,解剖组为70%(优效性log-rank P<0.0001)。
  • 单次消融术后无任何房性心律失常事件终点两组无显著差异。
  • 安全性复合终点(死亡、脑血管事件或治疗相关严重不良事件)两组无差异,定制组手术和消融时间延长一倍。

关键数值与推荐

  • 主要疗效终点:单次消融术后12个月无记录到的房颤(伴或不伴抗心律失常药物),定制组88% vs 解剖组70%(log-rank P<0.0001)。
  • 次要终点:无任何房性心律失常事件,两组无显著差异。
  • 安全性复合终点:死亡、脑血管事件或治疗相关严重不良事件,两组无差异。
  • 定制组手术和消融时间延长一倍。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Although pulmonary vein isolation (PVI) has become the cornerstone ablation procedure for atrial fibrillation (AF), the optimal ablation procedure for persistent and long-standing persistent AF remains elusive. Targeting spatio-temporal electrogram dispersion in a tailored procedure has been suggested as a potentially beneficial alternative to a conventional PVI-only procedure. In this multicenter, randomized, controlled, double-blind, superiority trial, patients with drug-refractory persistent AF were randomly assigned to a tailored ablation procedure targeting areas of spatio-temporal dispersion, as detected by an artificial intelligence (AI) algorithm, in addition to PVI (tailored arm, n = 187, 23% women) or to a conventional PVI-only procedure (anatomical arm, n = 183, 19% women). The primary efficacy endpoint was freedom from documented AF with or without antiarrhythmic drugs at 12 months after a single ablation procedure. Secondary endpoints included freedom from any atrial arrhythmic events, and the secondary composite safety endpoint consisted of death, cerebrovascular events, or treatment-related serious adverse events. One year post-procedure, the trial met its primary efficacy endpoint, which was achieved in 88% of patients in the tailored arm compared with 70% of patients in the anatomical arm (log-rank P < 0.0001 for superiority). However, no significant difference between arms was observed for the freedom from any atrial arrhythmia endpoint after one ablation. The safety endpoint did not differ between arms, with procedure and ablation times being twice as long in the tailored arm. These results show that AI-guided ablation of spatio-temporal dispersion areas in addition to PVI is superior to PVI alone in eliminating AF at 1-year follow-up in patients with persistent and long-standing persistent AF. Ablation of subsequent organized atrial tachycardias may be needed to maintain sinus rhythm long term. ClinicalTrials.gov identifier: NCT04702451 .

来源:Nat Med,查看原文。版权归原作者所有。

引用

  1. Deisenhofer I, Albenque JP, Busch S, et al. Artificial intelligence for individualized treatment of persistent atrial fibrillation: a randomized controlled trial. Nat Med. 2025. PMID: 39953289. doi:10.1038/s41591-025-03517-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。